NBA Deploys MightySat® Fingertip Pulse
Oximeters For All Campus Residents
Masimo (NASDAQ: MASI) today announced that it has entered into a
partnership with the National Basketball Association (NBA) to be
its official supplier of pulse oximetry. As teams return to play,
Masimo is supplying the NBA with MightySat® fingertip pulse
oximeters on its campus in Orlando, Florida.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20200730005587/en/
Gary Harris of the Denver Nuggets with
the Masimo MightySat® Fingertip Pulse Oximeter (Photo: Business
Wire)
Since arriving on campus in Orlando on July 7, and for the
duration of their stay, each campus resident, including players,
coaches, and team and league staff, will daily measure their oxygen
saturation, pulse rate, and respiration rate with MightySat as part
of the league’s health and safety protocols. MightySat is powered
by clinically proven, hospital-grade Masimo SET® Measure-through
Motion and Low Perfusion™ pulse oximetry technology.
Dr. John DiFiori, NBA Director of Sports Medicine, said,
“Fingertip pulse oximetry is an important component of the health
and safety protocols that govern the NBA’s re-start in Orlando. Our
players, teams and staff have been quick to adapt to the Masimo
technology to monitor their oxygen saturation rates, which is
contributing to keeping everyone on our campus safe and
healthy.”
Gary Harris, shooting guard for the Denver Nuggets, added, “I’ve
personally been using the MightySat in my training these past few
years. It’s incredibly accurate and has helped me get the most out
of my workouts and recovery. I’m glad to see it as part of our
health monitoring program as our team gets ready to resume the 2020
season.”
Joe Kiani, Founder and CEO of Masimo, said, “We are thrilled to
have the opportunity to provide our high performance monitoring
technology to such high performance athletes. For more than 30
years, we’ve specialized in innovative breakthrough hospital
monitoring solutions, and we are excited to continue our expansion
into new markets, bringing hospital-grade health and wellness
monitoring solutions to everyday users, elite athletes, and
organizations like the NBA.”
The NBA will re-start its season today at ESPN Wide World of
Sports in Orlando, Florida. The 22 teams with the best records as
of March 11, when the season was suspended, will compete in eight
preliminary “seeding” games before the 2020 NBA Playoffs begin on
August 17.
@MasimoInnovates | #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company
that develops and produces a wide array of industry-leading
monitoring technologies, including innovative measurements,
sensors, patient monitors, and automation and connectivity
solutions. Our mission is to improve patient outcomes and reduce
the cost of care. Masimo SET® Measure-through Motion and Low
Perfusion™ pulse oximetry, introduced in 1995, has been shown in
over 100 independent and objective studies to outperform other
pulse oximetry technologies.1 Masimo SET® has also been shown to
help clinicians reduce severe retinopathy of prematurity in
neonates,2 improve CCHD screening in newborns,3 and, when used for
continuous monitoring with Masimo Patient SafetyNet™ in
post-surgical wards, reduce rapid response team activations, ICU
transfers, and costs.4-7 Masimo SET® is estimated to be used on
more than 200 million patients in leading hospitals and other
healthcare settings around the world,8 and is the primary pulse
oximetry at 9 of the top 10 hospitals according to the 2019-20 U.S.
News and World Report Best Hospitals Honor Roll.9 Masimo continues
to refine SET® and in 2018, announced that SpO2 accuracy on RD SET®
sensors during conditions of motion has been significantly
improved, providing clinicians with even greater confidence that
the SpO2 values they rely on accurately reflect a patient’s
physiological status. In 2005, Masimo introduced rainbow® Pulse
CO-Oximetry technology, allowing noninvasive and continuous
monitoring of blood constituents that previously could only be
measured invasively, including total hemoglobin (SpHb®), oxygen
content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®),
Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen
Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient
Monitoring and Connectivity Platform, built from the ground up to
be as flexible and expandable as possible to facilitate the
addition of other Masimo and third-party monitoring technologies;
key Masimo additions include Next Generation SedLine® Brain
Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography
with NomoLine® sampling lines. Masimo’s family of continuous and
spot-check monitoring Pulse CO-Oximeters® includes devices designed
for use in a variety of clinical and non-clinical scenarios,
including tetherless, wearable technology, such as Radius-7® and
Radius PPG™, portable devices like Rad-67™, fingertip pulse
oximeters like MightySat® Rx, and devices available for use both in
the hospital and at home, such as Rad-97®. Masimo hospital
automation and connectivity solutions are centered around the
Masimo SafetyNet™, and include Iris Gateway®, Patient SafetyNet,
Replica™, Halo ION™, UniView™, UniView: 60™, and Masimo SafetyNet™.
Additional information about Masimo and its products may be found
at www.masimo.com. Published clinical studies on Masimo products
can be found at
www.masimo.com/evidence/featured-studies/feature/.
ORi and RPVi have not received FDA 510(k) clearance and are not
available for sale in the United States. The use of the trademark
Patient SafetyNet is under license from University HealthSystem
Consortium.
References
- Published clinical studies on pulse oximetry and the benefits
of Masimo SET® can be found on our website at
http://www.masimo.com. Comparative studies include independent and
objective studies which are comprised of abstracts presented at
scientific meetings and peer-reviewed journal articles.
- Castillo A et al. Prevention of Retinopathy of Prematurity in
Preterm Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on
the detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;Jan
8;338.
- Taenzer AH et al. Impact of pulse oximetry surveillance on
rescue events and intensive care unit transfers: a before-and-after
concurrence study. Anesthesiology. 2010:112(2):282-287.
- Taenzer A et al. Postoperative Monitoring – The Dartmouth
Experience. Anesthesia Patient Safety Foundation Newsletter.
Spring-Summer 2012.
- McGrath SP et al. Surveillance Monitoring Management for
General Care Units: Strategy, Design, and Implementation. The Joint
Commission Journal on Quality and Patient Safety. 2016
Jul;42(7):293-302.
- McGrath S et al. Inpatient Respiratory Arrest Associated With
Sedative and Analgesic Medications: Impact of Continuous Monitoring
on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14
Mar. DOI: 10.1097/PTS.0000000000000696.
- Estimate: Masimo data on file.
-
http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
Forward-Looking Statements
This press release includes forward-looking statements as
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, in connection with the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, among others, statements
regarding the potential effectiveness of Masimo MightySat®. These
forward-looking statements are based on current expectations about
future events affecting us and are subject to risks and
uncertainties, all of which are difficult to predict and many of
which are beyond our control and could cause our actual results to
differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors,
including, but not limited to: risks related to our assumptions
regarding the repeatability of clinical results; risks related to
our belief that Masimo's unique noninvasive measurement
technologies, including Masimo MightySat, contribute to positive
clinical outcomes and patient safety; risks related to our belief
that Masimo noninvasive medical breakthroughs provide
cost-effective solutions and unique advantages; risks related to
COVID-19; as well as other factors discussed in the "Risk Factors"
section of our most recent reports filed with the Securities and
Exchange Commission ("SEC"), which may be obtained for free at the
SEC's website at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove
correct. All forward-looking statements included in this press
release are expressly qualified in their entirety by the foregoing
cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of today's date. We do not undertake any obligation to update,
amend or clarify these statements or the "Risk Factors" contained
in our most recent reports filed with the SEC, whether as a result
of new information, future events or otherwise, except as may be
required under the applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200730005587/en/
Masimo Evan Lamb 949-396-3376 elamb@masimo.com
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Apr 2023 to Apr 2024